• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Annovis Bio Inc. (Amendment)

    11/28/23 4:05:14 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANVS alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    Amendment No. 1

     

    Under the Securities Exchange Act of 1934

     

      Annovis Bio, Inc.  
      (Name of Issuer)  
         
      Common Stock, $0.0001 par value  
      (Title of Class of Securities)  
         
     

    03615A108

     
      (CUSIP Number)  
         
      November 28, 2023  
      (Date of Event Which Requires Filing of this Statement)  

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 03615A108

     

    1.

    Names of Reporting Persons. AIGH Capital Management, LLC

    I.R.S. Identification Nos. of above persons (entities only).

     

    27-4413262

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

    4.

    Citizenship of Place of Organization

     

    Maryland

    Number of Shares Beneficially Owned by Each Reporting

    Person

    With

    5.

    Sole Voting Power

     

    435,000

    6.

    Shared Voting Power

     

     0

    7.

    Sole Dispositive Power

     

    435,0001

    8.

    Shared Dispositive Power

     

     

    9.

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    435,0001

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    4.24%

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

      1.

    Excludes 500,000 warrants to purchase common shares not exercisable due to beneficial ownership limitations.

     

     

     

     

    CUSIP No. 03615A108

     

    1.

    Names of Reporting Persons. AIGH Investment Partners, L.L.C.

    I.R.S. Identification Nos. of above persons (entities only).

     

     

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

    4.

    Citizenship of Place of Organization

     

    Delaware

    Number of Shares Beneficially Owned by Each Reporting

    Person

    With

    5.

    Sole Voting Power

     

    35,000

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    35,000

    8.

    Shared Dispositive Power

     

     

    9.

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    35,000

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    .34%

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

     

     

     

    CUSIP No. 03615A108

     

    1.

    Names of Reporting Persons. Orin Hirschman

    I.R.S. Identification Nos. of above persons (entities only).

     

     

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

    4.

    Citizenship of Place of Organization

     

    United States

    Number of Shares Beneficially Owned by Each Reporting

    Person

    With

    5.

    Sole Voting Power

     

    470,000

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    470,0001

    8.

    Shared Dispositive Power

     

     

    9.

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    470,0001

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    4.58%

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

      1.

    Excludes 500,000 warrants to purchase common shares not exercisable due to beneficial ownership limitations.

     

     

     

     

    ITEM 1:

     

    (a) Name of Issuer:

     

    Annovis Bio, Inc.

     

    (b) Address of Issuer’s Principal Executive Offices:

     

    1055 Westlakes Drive

    Berwyn, PA 19312

     

    ITEM 2:

     

    (a) Name of Person Filing:

     

    This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1 promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Act”):

     

      (i)

    AIGH Capital Management, LLC, a Maryland limited liability company (“AIGH LP”), as an Advisor or Sub-Advisor with respect to shares of Common Stock (as defined in Item 2(d) below) held by AIGH Investment Partners, L.P. and WVP Emerging Manger Onshore Fund, LLC;

       
      (ii)

    AIGH Investment Partners, L.L.C., a Delaware limited liability company (“AIGH LLC”), with respect to shares of Common Stock (as defined in Item 2(d) below) directly held by it;

       
      (iii)

    Mr. Orin Hirschman (“Mr. Hirschman”), who is the Managing Member of AIGH Capital Management, LLC and president of AIGH LLC, with respect to shares of Common Stock indirectly held by AIGH LP, directly by AIGH LLC and Mr. Hirschman and his family directly.

     

    AIGH Capital Management LLC., AIGH Investment Partners LLC, and Mr. Hirschman are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    (b) Address of Principal Business Office or, if None, Residence:

     

    The principal office and business address of AIGH Investment Partners, L.P., AIGH Investment Partners LLC, and Mr. Hirschman is:

     

    6006 Berkeley Avenue

    Baltimore MD 21209

     

    (c) Citizenship:

     

    See Item 2(a) above and Item 4 of each cover page.

     

    (d) Title of Class of Securities:

     

    Common Stock, $0.0001 par value

     

    (e) CUSIP Number:

     

    03615A108

     

     

     

     

    ITEM 3: IF THIS STATEMENT IS FILED PURSUANT TO §§240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
           
      (e) ☒ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ A non-U.S. institution, in accordance with §240.13d-1(b)(1)(ii)(J);
           
      (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).
         

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________________.

     

    ITEM 4: OWNERSHIP.

     

    See Item s 5,6,7,8 and 9 of each cover page.

     

    ITEM 5: OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒

     

    ITEM 6: OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

     

    Not applicable.

     

    ITEM 7: IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

     

    Not applicable.

     

    ITEM 8: IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

     

    Not applicable.

     

    ITEM 9: NOTICE OF DISSOLUTION OF GROUP.

     

    Not applicable.

     

    ITEM 10: CERTIFICATIONS.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 28, 2023 By: /s/ Orin Hirschman
        Orin Hirschman,
        Individually and as (a) managing member of AIGH Capital Management LLC.: and (b) president of AIGH Investment Partners LLC.

     

     

    Get the next $ANVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANVS

    DatePrice TargetRatingAnalyst
    2/10/2025Buy → Hold
    D. Boral Capital
    10/25/2024$25.00Hold → Buy
    Maxim Group
    12/29/2023$36.00Buy
    Canaccord Genuity
    7/7/2021$45.00 → $150.00Buy
    Maxim Group
    More analyst ratings

    $ANVS
    Financials

    Live finance-specific insights

    See more
    • Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson's Disease

      Data Shows Statistically Significant Improvements in Speed and Motor Function in PD PatientsAnnovis Bio to Request Meeting with FDA on Next Steps in Clinical DevelopmentInvestor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ETBerwyn, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 PD patients, which found that once-daily ANVS401 was superior to placebo in improving motor funct

      10/5/21 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANVS
    Leadership Updates

    Live Leadership Updates

    See more
    • Annovis Bio Appoints Hui Liu as Director of Biostatistics

      MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment Hui Liu as Director of Biostatistics. "Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3 AD trial advances, reinforces our commitment to scientific excellence," said Cheng Fang, Ph.D., Senior Vice President, Research and Development. "Her statistical expertise will help ensure the integrity of our data and support robust regulatory submissions as we move to

      4/29/25 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist

      MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct, reporting, and successful completion of Annovis' clinical trials. "We are thrilled to welcome Matthew Peterson to our team," said Cheng Fang, Ph.D., Senior Vice President, Research and Development,

      11/7/24 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Appoints Andrew Walsh as Vice President Finance

      BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD) today announced the appointment of Andrew Walsh as VP, Finance.  "We remain steadfast in advancing our lead candidate buntanetap, as we gear up to receive pivotal data from both our Alzheimer's and Parkinson's clinical trials in 2024. The addition of Andrew Walsh to our team marks another step in our growth plans," said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "Andrew brings 12 years of extensive experience in finance operations, adding a

      12/1/23 7:30:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Annovis Bio downgraded by D. Boral Capital

      D. Boral Capital downgraded Annovis Bio from Buy to Hold

      2/10/25 8:18:59 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio upgraded by Maxim Group with a new price target

      Maxim Group upgraded Annovis Bio from Hold to Buy and set a new price target of $25.00

      10/25/24 7:56:01 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Annovis Bio with a new price target

      Canaccord Genuity initiated coverage of Annovis Bio with a rating of Buy and set a new price target of $36.00

      12/29/23 7:03:31 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANVS
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Annovis Bio Inc.

      DEFA14A - Annovis Bio, Inc. (0001477845) (Filer)

      5/1/25 5:20:16 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Annovis Bio Inc.

      DEF 14A - Annovis Bio, Inc. (0001477845) (Filer)

      4/30/25 5:20:39 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Annovis Bio, Inc. (0001477845) (Filer)

      3/27/25 4:35:31 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director White Mark K.

      4 - Annovis Bio, Inc. (0001477845) (Issuer)

      7/3/24 5:18:10 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mccarthy Reid

      4 - Annovis Bio, Inc. (0001477845) (Issuer)

      7/3/24 5:17:22 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Maccecchini Maria-Luisa gifted 30,000 shares, decreasing direct ownership by 3% to 1,068,459 units (SEC Form 4)

      4 - Annovis Bio, Inc. (0001477845) (Issuer)

      7/3/24 5:16:55 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Annovis Bio Inc. (Amendment)

      SC 13G/A - Annovis Bio, Inc. (0001477845) (Subject)

      11/28/23 4:05:14 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Annovis Bio Inc.

      SC 13G - Annovis Bio, Inc. (0001477845) (Subject)

      11/8/23 7:02:36 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Annovis Bio Appoints Hui Liu as Director of Biostatistics

      MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment Hui Liu as Director of Biostatistics. "Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3 AD trial advances, reinforces our commitment to scientific excellence," said Cheng Fang, Ph.D., Senior Vice President, Research and Development. "Her statistical expertise will help ensure the integrity of our data and support robust regulatory submissions as we move to

      4/29/25 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

      MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that on March 26, 2025, it received notice (the "Notice") from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE's Listed Company Manual due to the fact that the Company's average global market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholde

      3/27/25 4:30:00 PM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

      MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its participation in the AD/PD™ 2025 taking place April 1-5 in Vienna. "We are at a pivotal moment in our company's journey as we have entered the late clinical stages for both Alzheimer's and Parkinson's. It is incredibly rewarding to see our work bring us here, once again supporting that our drug is efficacious and safe across both indications," commented Maria Maccecchini, Ph.D., Founder and CEO of Annovis. "A

      3/25/25 8:00:00 AM ET
      $ANVS
      Biotechnology: Pharmaceutical Preparations
      Health Care